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INTRODUCTION
There	were	records	that	ancient	civilizations	in	Egypt,	India,	
China,	and	Greek	employed	sun	exposure	to	treat	skin	dis-
eases,	rickets	and	even	psychosis.	However,	it	has	not	been	
employed	widely	in	medicine	until	the	eighteen	century	[1].	In	
1903,	The	group	of	Von	Tappeiner	found	favorable	result	after	
photodynamic	therapy	(PDT)	using	several	dyes:	eosin,	fluo-
rescein,	sodium	dichloroanthracene	disulfonate	and	‘Grubler’
s	Magdalene	red’	with	light	on	skin	diseases,	such	as	lupus	
of	the	skin	and	condylomata	of	the	female	genitalia	[2].	Von	
Tappeiner	and	Jodlbauer	[3,4]	proved	the	necessity	of	oxygen	
in	this	phenomenon	in	1904	and	in	1907,	they	explained	this	
phenomenon	with	oxygen-dependent	photosensitization	
and	adopted	a	term	“photodynamic	therapy”.	Although	these	
showed	good	results,	no	further	reports	were	forthcoming	
because	of	the	emergence	of	ionizing	radiation	in	cancer	
therapy.	Diamond	et	al.	[5]	reported	in	1972	that	hematopor-
phyrin	activated	by	white	light	may	lead	to	regression	of	an	
experimental	glioma	in	rats.	Finally,	Dougherty	et	al.	[6]	initi-
ated	clinical	trials	of	PDT	in	25	patients	with	cutaneous	and	
subcutaneous	tumors	and	confirmed	the	effectiveness	of	PDT.	
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Objective:	Photodynamic	therapy	(PDT)	has	been	used	for	superficial	neoplasms	and	its	usage	has	been	recently	extended	to	
deeper	lesions.	The	purpose	of	this	study	was	to	observe	whether	or	not	PDT	can	cure	breast	cancer	in	the	solid	tumor	model,	
and	to	define	the	critical	point	of	laser	amount	for	killing	the	cancer	cells.
Methods: Twenty	four	BALB/c	mouse	models	with	subcutaneous	EMT6	mammary	carcinomas	were	prepared.	Mice	were	
divided	into	eight	groups	depending	on	the	amount	of	illumination,	and	the	tumor	size	was	between	8	mm	and	10	mm.	We	
began	by	peritoneal	infiltration	with	a	photosensitizer	48	hours	prior	to	applying	the	laser	light,	and	then	we	applied	a	non-
thermal	laser	light.	The	energy	was	from	350	J/cm
2	to	30	J/cm
2	to	the	cancer.	
Results: Regardless	of	the	tumor	size	from	8	mm	to	10	mm,	all	mice	apparently	showed	positive	results	via	PDT.	We	also	did	not	
find	any	recurrence	over	90	J/cm
2.	In	all	models,	the	color	of	the	breast	cancer	lesions	began	to	vary	to	dark	on	2	days	post	PDT	
and	the	tumor	regression	began	simultaneously.	Also,	we	confirmed	the	complete	regression	of	the	breast	cancer	21	days	after	
PDT.	
Conclusion: We	confirmed	that	PDT	may	treat	breast	cancers	that	are	sized	less	10	mm	in	mouse	models.	The	moderate	energy	
to	destruct	the	breast	cancer	cells	may	be	90	J/cm
2.	Therefore,	we	can	expect	that	PDT	may	be	utilized	to	treat	breast	cancer,	
but	we	need	more	experience,	skills	and	processing	for	clinical	trials.	
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After	the	1990s,	PDT	has	rapidly	become	a	relevant	method	
both	in	clinical	application	and	basic	mechanistic	understand-
ing	in	treating	the	skin	and	superficial	cancerous	lesions.	
Now	PDT	with	Photofrin	has	been	approved	by	the	US	Food	
and	Drug	Administration	(FDA)	and	numerous	other	health	
agencies	throughout	the	world	for	obstructive	esophageal	
cancer	and	lung	cancer,	bladder	cancer,	etc	[7].	Recently	PDT	
has	been	clinically	applicable	in	superficial	lesions	like	skin	le-
sions,	cervical	intraepithelial	lesions	and	hollowed	organs.	In	
our	gynecologic	department,	we	have	much	cumulative	data	
of	the	effect	of	PDT	on	cervical	intraepithelial	neoplasia	and	
have	started	to	treat	breast	cancer.	However,	there	are	to	date	
no	data	of	the	effect	of	PDT	in	the	field	of	the	breast.	So	we	
hereby	examined	the	response	of	breast	cancers	to	PDT	with	
Photofrin	using	murine	models.	
MATERIALS AND METHODS
1. Tumor model
Breast	cancer	cells	(EMT-6)	were	obtained	from	the	Ameri-
can	Type	Culture	Collection	(ATCC;	Manassas,	VA,	USA)	and	
maintained	in	Waymouth’s	media	supplemented	with	15%	
fetal	bovine	serum	and	1%	penicillin-streptomycin	solution.	
6-week-old	female	BALB/c	mice	(Samtako,	Osan,	Korea)	were	
anesthetized	with	ketamine	and	1.5×10
5	cells	were	subcuta-
neously	injected	into	the	lower	back.	For	each	experiment,	3	
mice	were	used	in	each	experimental	group	and	treatment	
was	started	when	the	average	tumor	size	was	approximately	
250	mm
3.	The	study	was	approved	by	the	local	animal	welfare	
committee.
2. Protocol of PDT
We	began	by	peritoneal	infiltration	of	photosensitizer	(Pho-
tofrin	[HpD],	Axcan	Pharma	Inc.,	Mont-Saint-Hilaire,	Canada)	
with	5	mg/kg,	48	hours	later,	we	applied	a	non-thermal	laser	
light	(Ceralas	Diode	Laser	632	System,	Biolitec,	Jena,	Germany)	
(Fig.	1).	The	amount	of	energy	was	from	350	J/cm
2	to	30	J/cm
2	
on	the	cancer	cell	and	the	margin	of	laser	was	a	little	bit	wider	
than	the	cancer	lesion	because	cancer	can	recur	easily.	Then	
we	evaluated	the	effects	of	this	procedure	every	3	days.	The	
control	group	was	not	needed	because	if	the	breast	cancer	
was	not	irradiated,	the	growth	of	cancer	will	certainly	con-
tinue.	
RESULTS
Just	after	PDT,	gray	discoloration	was	shown	at	the	illumina-
tion	site.	The	color	of	illumination	site	including	breast	cancer	
began	to	darken	2	days	post	PDT	and	the	cancer	regressed	si-
multaneously.	The	tumor	size	was	from	8	mm	to	10	mm,	how-
ever,	regardless	of	the	tumor	size	all	cancer	models	showed	
effectiveness	of	the	PDT.	However,	tissue	deformities	were	
noticed	in	the	240	and	350	J/cm
2	group	(Fig.	2).	We	confirmed	
the	complete	remission	21	days	post	PDT	from	180	to	90	J/
cm
2	(Fig.	3).	
From	350	J/cm
2	to	90	J/cm
2,	all	mice	models	showed	com-
plete	remission.	However	one	out	of	three	mice	showed	no	
Fig. 1. Photodynamic therapy illumination onto the cancer with a 
non-thermal laser light (Ceralas Diode Laser 932 System).
Fig. 2. Complete remission was shown in 
350 and 240 J/cm
2 but tissue deformities 
were noticed because of high energy (21 
days after photodynamic therapy).Effect of photodynamic therapy on breast cancer model
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response	in	the	60	J/cm
2	group	(Fig.	4)	and	in	the	30	J/cm
2	group,	
the	effectiveness	of	PDT	did	not	show	in	all	mice	(Fig.	5).	So,	we	
determined	that	the	moderate	energy	required	to	treat	breast	
cancer	sized	less	than	10	mm	is	around	90	J/cm
2.	We	did	not	
find	any	recurrence	in	the	group	that	received	energy	more	
than	90	J/cm
2.	So,	the	energy	of	90	J/cm
2	may	be	minimum	
energy	required	to	destruct	the	breast	cancer	cells	completely.
DISCUSSION
PDT	is	a	treatment	that	can	eradicate	premalignant	and	
early-staged	cancer	and	can	reduce	the	tumor	size	in	end-
staged	cancers.	The	advantage	of	PDT	is	that	it	is	a	minimally	
invasive	method	that	can	affect	the	selective	area	and	there	
is	no	limitation	of	repetitions	and	little	complications.	It	is	also	
Fig. 3. Complete remission shown in 
180, 150, 120, and 90 J/cm
2 (21 days after 
photodynamic therapy).
Fig. 4. The first and third mice showed 
complete remission but the second one 
(arrow) revealed no response with 60 J/
cm
2 (21 days after photodynamic therapy).
Fig. 5. All mice showed no response. 
Cancer growth was continued with 
30 J/cm
2 (21 days after photodynamic 
therapy).Tae-Gyu Ahn, et al.
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has	a	merit	in	that	PDT	is	applicable	when	systemic	chemo-
therapy	and	surgery	are	not	possible	[8].	PDT	mechanism	can	
be	explained	by	two	parts:	uptake	of	sensitizers	and	tumor	
destruction	by	laser	light.	
1. PDT
The	first	approval	of	PDT	was	in	Canada	in	1993	for	the	treat-
ment	of	bladder	cancers.	Esophageal	cancer	was	approved	by	
the	US	FDA	in	December	1995,	and	early	non-small	cell	lung	
cancer	in	1998	followed	by	Barrett's	esophagus	[9,10].	Even	
though	PDT	data	in	gynecology	are	not	sufficient,	several	in-
stitutes	already	have	collected	much	data	and	some	gyneco-
logic	departments	have	tried	to	begin	PDT.	Several	photosen-
sitizers	that	can	be	accumulated	in	the	tumor	tissue	selectively	
have	been	introduced,	but	the	exact	mechanisms	of	each	
photosensitizers	are	different.	Porphyrin	derivatives	can	be	
localized	in	tumors	when	injected	into	the	bloodstream	[11].	
In	the	hematoporphyrin	derivative	and	its	improved	version,	
called	Photofrin,	are	still	the	most	widely	used	photosensitiz-
ers	in	PDT	of	tumors	[12].	Among	photosensitizers,	Photofrin	
has	been	used	in	our	department	for	the	last	ten	years	and	
we	assumed	that	PDT	with	Photofrin	may	be	have	effective	in	
breast	cancers	also.	In	our	department,	we	began	to	operate	
on	breast	cancer	from	2010	and	we	tried	to	adopt	PDT	in	the	
breast	lesions.	So,	we	conducted	this	study.	We	applied	the	
same	protocol	that	was	used	in	patients	to	the	mice	model.	
The	drug	is	injected	intravenously	and	after	48	hours,	applica-
tion	of	irradiation	to	tumors	was	performed	with	630	nm	wave	
length	of	laser	[13,14].
2. PDT and breast cancer
PDT	has	been	applicable	in	the	field	so	that	physicians	can	
directly	approach	the	lesion.	The	breast	area	is	also	able	to	
be	approach	easily,	and	we	can	adopt	PDT	for	the	breast.	The	
first	line	treatment	for	breast	cancer	is	surgery	and	can	lead	
to	changes	in	the	breast	shape.	Thus,	if	there	is	a	non-invasive	
procedure	that	is	able	to	destroy	cancer	cells,	it	would	be	pref-
erable.	Even	though	there	were	no	reports	about	PDT	for	the	
breast	cancer	as	the	first	line	therapy,	several	studies	showed	
reliable	effects	of	PDT	in	locally	recurrent	breast	cancer	or	
chest	wall	recurrence	[15-17].	Thus,	we	may	assume	through	
this	data	that	breast	cancer	cells	may	be	eradicated	by	PDT.	
Also,	PDT	is	applicable	during	surgery.	After	mastectomy,	PDT	
can	be	applied	on	the	bed	of	the	previous	lesion	for	prevent-
ing	recurrence.	The	usual	laser	fiber	can	be	used	when	PDT	is	
applied	to	the	skin	area	such	as	chest	wall	recurrence.	But	if	
we	try	to	treat	the	lesion	that	is	located	under	the	skin,	a	spe-
cific	laser	fiber	is	needed	such	as	an	interstitial	type	that	can	
penetrate	the	skin	and	reach	the	lesion.	So,	research	about	the	
specific	laser	fiber	is	mandatory	to	destroy	lesions	under	the	
skin.	
From	our	study,	first	we	can	reconfirm	the	PDT	effects	to	
destroy	breast	cancer	cells.	Next,	discovery	of	proper	energy	
is	very	important	because	the	amount	of	energy	should	be	
different	for	each	tissue	and	organ	(for	example,	we	applied	
240	J/cm
2	to	uterine	cervical	cancer).	In	addition,	when	photo-
chemical	internalization	(PCI)	concept	is	added	to	traditional	
PDT,	the	result	of	cancer	cell	destruction	can	be	maximized.	
For	performing	PCI,	chemotherapeutic	agents	should	be	
added	before	PDT.	When	previously	infiltrated	sensitizers	are	
exposed	to	light,	sensitizers	begin	to	activate	and	produce	
free	radicals.	Finally,	endocytosed	molecules	or	chemothera-
peutic	agents	may	be	released	and	attack	cancer	cells	directly	
before	being	degraded	by	lysosomes	[18].	Thus,	if	we	add	this	
PCI	concept	with	the	traditional	PDT	in	our	next	trial,	we	can	
assume	that	the	results	will	improve	markedly.	
In	our	research	we	were	able	to	confirm	the	effect	of	PDT	
on	breast	cancer	models	and	found	out	the	proper	amount	
of	energy	of	90	J/cm
2	in	less	than	10	mm	sized	breast	cancers.	
However,	we	assume	that	we	need	more	technical	practice	
and	clinical	data	to	be	able	to	apply	PDT	to	humans.	
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